The National Reimbursement Drug List (NRDL) has long been a critical vehicle for pharmaceuticals in China, providing patient access to treatments through centralized public insurance.

Since entering the World Trade Organization, China’s Pharmaceutical industry has experienced rapid growth in value, from $123.7 billion in 2016 to an estimated $573.5 billion in 2022

In an article, published on Pharmexec, Anaïs Frappé, Amy Morgan and Crystal Leung, review market access opportunities in China through private payers, and how Commercial Health Insurance (CHI) can bring value before, during, and after NRDL inclusion.